-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LM-302 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Forigerimod Acetate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Forigerimod Acetate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Forigerimod Acetate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)...
-
Product Insights
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024
Empower your strategies with our Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Methicillin-resistant Staphylococcus aureus (MRSA) infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections; others are hospital-aquired (HA-MRSA). Risk factors for MRSA infection are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin...
-
Product Insights
NewNeuropathy – Drugs In Development, 2024
Empower your strategies with our Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions...
-
Product Insights
NewPeripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2024
Empower your strategies with our Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral neuropathy refers to a condition that involves damage or dysfunction of the peripheral nerves, resulting in various sensory, motor, and autonomic symptoms. These nerves transmit signals between the central nervous system (brain and spinal cord) and the rest of the body, controlling muscle movements, sensation, and organ function. There are different types of peripheral neuropathy, each affecting specific nerves...
-
Product Insights
NewAspergillosis – Drugs In Development, 2024
Empower your strategies with our Aspergillosis – Drugs In Development, 2024 report and make more profitable business decisions. Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss, and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma, and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungals, and surgery. The Aspergillosis drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewMycoses – Drugs In Development, 2024
Empower your strategies with our Mycoses – Drugs In Development, 2024 report and make more profitable business decisions. Mycoses, also known as fungal infections, encompass a diverse group of diseases caused by fungi. These infections can affect various tissues in the body, including the skin, nails, and internal organs. Superficial mycoses, like athlete's foot and ringworm, involve the outer layers, while systemic mycoses can affect deeper tissues and may be more severe, particularly in individuals with weakened immune systems. Candidiasis is...
-
Product Insights
NewChronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2024
Empower your strategies with our Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic inflammatory demyelinating polyneuropathy (CIDP), also called as chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal; orthostatic dizziness; and tingling and numbness of hands...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-101 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-101 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-101 in Metastatic Colorectal Cancer Drug Details: LB-101 is under...